Generali Investments Management Co LLC Takes $385,000 Position in Revvity, Inc. (NYSE:RVTY)

Generali Investments Management Co LLC bought a new position in shares of Revvity, Inc. (NYSE:RVTY - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 3,447 shares of the company's stock, valued at approximately $385,000.

Several other hedge funds and other institutional investors have also modified their holdings of RVTY. Assetmark Inc. grew its stake in shares of Revvity by 3,700.0% during the fourth quarter. Assetmark Inc. now owns 266 shares of the company's stock worth $30,000 after purchasing an additional 259 shares during the period. Continuum Advisory LLC increased its position in Revvity by 2,972.7% during the third quarter. Continuum Advisory LLC now owns 338 shares of the company's stock worth $43,000 after buying an additional 327 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its position in shares of Revvity by 55.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company's stock valued at $43,000 after purchasing an additional 138 shares during the last quarter. Avior Wealth Management LLC grew its position in shares of Revvity by 7,980.0% in the third quarter. Avior Wealth Management LLC now owns 404 shares of the company's stock valued at $52,000 after purchasing an additional 399 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in shares of Revvity by 33.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 522 shares of the company's stock valued at $58,000 after purchasing an additional 131 shares during the last quarter. Institutional investors own 86.65% of the company's stock.

Insider Buying and Selling

In related news, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the sale, the insider now directly owns 33,400 shares of the company's stock, valued at approximately $4,232,782. This represents a 31.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Tajinder S. Vohra sold 5,492 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total transaction of $641,520.52. Following the sale, the insider now directly owns 19,652 shares in the company, valued at $2,295,550.12. This trade represents a 21.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by company insiders.

Remove Ads

Analyst Ratings Changes

Several equities research analysts have weighed in on RVTY shares. Bank of America upgraded Revvity from a "neutral" rating to a "buy" rating and set a $138.00 target price for the company in a research note on Friday, December 13th. Sanford C. Bernstein downgraded Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price target for the company. in a report on Friday, January 10th. Barclays raised their target price on Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. KeyCorp raised their price target on shares of Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Finally, Raymond James reissued an "outperform" rating and set a $145.00 target price (up previously from $140.00) on shares of Revvity in a research report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Revvity currently has a consensus rating of "Moderate Buy" and a consensus target price of $136.25.

Revvity Price Performance

NYSE RVTY traded up $0.20 on Friday, reaching $107.18. The company had a trading volume of 1,281,291 shares, compared to its average volume of 850,133. The firm's 50 day moving average price is $116.44 and its 200 day moving average price is $117.54. Revvity, Inc. has a 12 month low of $97.32 and a 12 month high of $129.50. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $12.88 billion, a PE ratio of 48.50, a price-to-earnings-growth ratio of 3.82 and a beta of 1.06.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, topping analysts' consensus estimates of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same quarter in the previous year, the firm posted $1.25 earnings per share. As a group, equities analysts predict that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be paid a dividend of $0.07 per share. The ex-dividend date is Thursday, April 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.26%. Revvity's dividend payout ratio (DPR) is presently 12.67%.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.